-
1
-
-
0036405496
-
Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease
-
Blum D., Galas M.-C., Gall D., Cuvelier L., Schiffman S.N. Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Neurobiol. Dis. 10:2002;410-426
-
(2002)
Neurobiol. Dis.
, vol.10
, pp. 410-426
-
-
Blum, D.1
Galas, M.-C.2
Gall, D.3
Cuvelier, L.4
Schiffman, S.N.5
-
2
-
-
0035095231
-
Genomic multi-level nutrient-sensing pathways
-
Brudnak M.A. Genomic multi-level nutrient-sensing pathways. Med. Hypotheses. 56:2001;194-199
-
(2001)
Med. Hypotheses
, vol.56
, pp. 194-199
-
-
Brudnak, M.A.1
-
3
-
-
0034913807
-
Application of genomeceuticals to the molecular and immunological aspects of autism
-
Brudnak M.A. Application of genomeceuticals to the molecular and immunological aspects of autism. Med. Hypotheses. 57:2001;186-191
-
(2001)
Med. Hypotheses
, vol.57
, pp. 186-191
-
-
Brudnak, M.A.1
-
4
-
-
1842427203
-
Creatine: Are the benefits worth the risk?
-
Brudnak M.A. Creatine: are the benefits worth the risk? Toxicol. Lett. 150:2004;123-130
-
(2004)
Toxicol. Lett.
, vol.150
, pp. 123-130
-
-
Brudnak, M.A.1
-
5
-
-
0036095642
-
Opposite actions of caffeine and creatine on muscle relaxation time in humans
-
Hespel P., Op 't Eijnde B., Van Leemputte M. Opposite actions of caffeine and creatine on muscle relaxation time in humans. J. Appl. Physiol. 92:2002;513-518
-
(2002)
J. Appl. Physiol.
, vol.92
, pp. 513-518
-
-
Hespel, P.1
Op Eijnde 'T, B.2
Van Leemputte, M.3
-
6
-
-
0009534249
-
Placebo-controlled trial of creatine in Huntington's disease
-
Kieburtz K. Huntington Study Group Placebo-controlled trial of creatine in Huntington's disease. Neurology. 56(Suppl. 3):2001;A386
-
(2001)
Neurology
, vol.56
, Issue.SUPPL. 3
, pp. 386
-
-
Kieburtz, K.1
Study Group, H.2
-
8
-
-
0037677341
-
Creatine therapy for Huntington's disease: Clinical and MRS findings in a 1-year pilot study
-
Tabrizi S.J., Blamire A.M., Manners D.N., Rajagopalan B., Styles P., Schapira A.H.V., Warner T.T. Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology. 61:2003;141-142
-
(2003)
Neurology
, vol.61
, pp. 141-142
-
-
Tabrizi, S.J.1
Blamire, A.M.2
Manners, D.N.3
Rajagopalan, B.4
Styles, P.5
Schapira, A.H.V.6
Warner, T.T.7
-
9
-
-
0030070796
-
Caffeine counteracts the ergogenic action of muscle creatine loading
-
Vandenberghe K., Gillis N., Van Leemputte M., Van Hecke P., Vanstapel F., Hespel P. Caffeine counteracts the ergogenic action of muscle creatine loading. J. Appl. Physiol. 80:1996;452-457
-
(1996)
J. Appl. Physiol.
, vol.80
, pp. 452-457
-
-
Vandenberghe, K.1
Gillis, N.2
Van Leemputte, M.3
Van Hecke, P.4
Vanstapel, F.5
Hespel, P.6
-
10
-
-
0141959170
-
Creatine supplementation in Huntington's disease-a placebo-controlled pilot trial
-
Verbessem P., Lemiere J., Eijnde B.O., Swinnen S., Vanhees L., Van Leemputte M., Hespel P., Dom R. Creatine supplementation in Huntington's disease-a placebo-controlled pilot trial. Neurology. 61:2003;925-930
-
(2003)
Neurology
, vol.61
, pp. 925-930
-
-
Verbessem, P.1
Lemiere, J.2
Eijnde, B.O.3
Swinnen, S.4
Vanhees, L.5
Van Leemputte, M.6
Hespel, P.7
Dom, R.8
-
11
-
-
0033935979
-
Creatine and creatinine metabolism
-
Wyss M., Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol. Rev. 80:2000;1107-1213
-
(2000)
Physiol. Rev.
, vol.80
, pp. 1107-1213
-
-
Wyss, M.1
Kaddurah-Daouk, R.2
-
12
-
-
0037129967
-
Health implications of creatine: Can oral creatine supplementation protect against neurological and atherosclerotic disease?
-
Wyss M., Schulze A. Health implications of creatine: can oral creatine supplementation protect against neurological and atherosclerotic disease? Neuroscience. 112:2002;243-260
-
(2002)
Neuroscience
, vol.112
, pp. 243-260
-
-
Wyss, M.1
Schulze, A.2
|